Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer

Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer

0:00

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of abiraterone acetate therapy presented at the 2014 ASCO Genitourinary Cancers Symposium. Karim Fizazi MD PhD, Professor of Medicine and Head of the Department of Cancer Medicine at the Institut Gustave Roussy in Villejuif, Paris, discussed his group’s findings and the implications for using new generation androgen deprivation therapy in the advanced stages of prostate cancer.

CONTACT:
Dr. Karim Fizazi MD PhD
Head of the Department of Cancer Medicine
Institut Gustave Roussy, Villejuif, Paris

SOURCE:
Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.

LINK:
Web link: http://meetinglibrary.asco.org/content/123754-142

TAGS:
Gleason score, abiraterone, metastatic castration-resistant prostate cancer, ASCO GU 2014 Symposium San Francisco, anti-androgen therapy, androgen deprivation,

Related Episodes

Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer

Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies.  I’m Peter Goodwin wi